Conference call today at 9:00 am ET2Q 2025 revenues of $76.5M, +6% v. 2Q 2024YTD 2025 revenues of $154.9M, +12% v. YTD ...

"ICON’s strong results in this report reflect the dedication, expertise, and innovation that drive our teams globally," said Steve Cutler, CEO. "Our consistent leadership in phase 1 clinical ...

The benchmarking report used a rigorous methodology to ensure results reflected ICON’s true impact and performance in the competitive phase 1 landscape. ISR screened participants to ensure relevance ...

Icon Business Operations executive vice-president Dr Gareth Milborrow said: “Mural Health’s range of payment methods, unique approach to payment structure, and introduction of a fee-free ...

Fintel reports that on July 24, 2025, Baird upgraded their outlook for ICON Public Limited (NasdaqGS:ICLR) from Neutral to ...

ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research organisations (CRO) for phase 1 ...